Kirin vs Takeda Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kirin Holdings Co. Ltd. (2503.JP)

Q3 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

September 20266 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Latest6 Aug – 6 Oct 2026

▲4

Kirin buys Canadian supplement giant, raises outlook, and rides beer tax cut

Kirin to buy Canadian supplement giant Jamieson for ~¥218bn Kirin will acquire all of Jamieson Wellness, Canada's big supplement maker, for about 218 billion yen. This adds a North American base in the world's largest supplement market, building on Blackmores and Fancl to strengthen health as a long-term growth engine. The deal needs shareholder and court approval, so it is not yet final.
This is the period's biggest strategic move and directly supports Kirin's health-business growth story.
Kirin lifts full-year forecast on record revenue Kirin raised its full-year forecast after interim revenue hit a record, with health, medical, beer and soft drinks all selling more and earning more. That broad-based profit growth tells investors the core businesses are healthy, which supports the share price.
A raised forecast is a direct, company-specific signal of improving earnings power.
October beer tax cut lowers Kirin Ichiban price From October, Japan unified beer taxes: regular beer gets about 9 yen cheaper per 350ml can, while cheaper happoshu and third-category beers get about 7 yen pricier. Kirin's flagship Ichiban Shibori drops from roughly 237 to 228 yen, which should pull drinkers back to beer and help Kirin's main product.
The tax change directly improves the price competitiveness of Kirin's biggest beer brand.
Kirin's Hyoketsu taps fast-growing US RTD market Americans are drinking less beer and wine but more ready-to-drink canned cocktails, a market growing 14% a year to about $22bn. Kirin has sold Hyoketsu in some US regions since March, joining Suntory and Asahi. Competition is intense, but the trend gives Kirin a new overseas growth channel.
It shows a new demand driver abroad for Kirin's drinks business.

Takeda Pharmaceutical Co. Ltd. (4502.JP)

Q3 202613 Jul – 14 Sep 2026

▲4

Takeda's Q3: New Drug Launches and AI Partnerships Drive Growth

Qdenga approved in India Takeda's dengue vaccine Qdenga became India's first approved dengue vaccine, opening a large new market and boosting the company's global vaccine business.
This is a new approval that expands Takeda's vaccine reach and revenue potential.
ORZEYFUL launched in US and Japan ORZEYFUL, a first-in-class narcolepsy therapy, launched in the US and Japan, offering a new treatment option and adding a new revenue stream for Takeda.
This is a new product launch that directly contributes to Takeda's sales growth.
MIMRYLO approved for polycythemia vera MIMRYLO received FDA approval for polycythemia vera, expanding Takeda's oncology portfolio. However, it requires up to $1.15 billion in milestone payments to a partner.
This is a new approval that adds a new drug to Takeda's lineup, though with a financial obligation.
AI-developed zasocitinib beats Sotyktu in Phase 3 Zasocitinib, developed using AI, outperformed Sotyktu in a Phase 3 trial for psoriasis, and its NDA was accepted under priority review, with an FDA decision expected in early 2027.
This is a major clinical win that could lead to a new blockbuster drug, though approval is not yet certain.

August 202615 Aug – 14 Sep 2026

▲4

Takeda's pipeline wins and AI edge drive the story

AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.
It shows a technology edge that can drive future revenue and investor optimism.
Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.
A new approval expands Takeda's commercial portfolio and revenue potential.
FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.
A major U.S. approval adds a new growth driver, offset by milestone payments.
FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.
It advances a key pipeline drug toward market, a clear positive catalyst.

Latest15 Aug – 14 Sep 2026

▲4

Takeda's pipeline wins and AI edge drive the story

AI-developed psoriasis drug shines in Phase 3 Takeda's AI-developed psoriasis drug zasocitinib beat Bristol-Myers Squibb's Sotyktu in a Phase 3 trial. This shows Takeda's bet on AI drug discovery is paying off, which can lift the stock by raising hopes for a valuable new treatment.
It shows a technology edge that can drive future revenue and investor optimism.
Japan approves first-in-class narcolepsy drug Japan approved ORZEYFUL for narcolepsy type 1, the first drug there to treat the underlying cause. This adds a new product to Takeda's lineup and can boost sales, supporting the stock price.
A new approval expands Takeda's commercial portfolio and revenue potential.
FDA approves first-in-class blood cancer drug Takeda won FDA approval for MIMRYLO (rusfertide) for polycythemia vera, a blood cancer. This is a new treatment option that can drive future sales, though Takeda must pay up to $1.15 billion in milestones to its partner.
A major U.S. approval adds a new growth driver, offset by milestone payments.
FDA accepts zasocitinib NDA under priority review The FDA accepted Takeda's application for zasocitinib in plaque psoriasis under priority review, with a decision expected in early 2027. This speeds up the path to a potential approval, which can lift the stock as investors anticipate a new blockbuster.
It advances a key pipeline drug toward market, a clear positive catalyst.

July 202613 Jul – 11 Aug 2026

▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.
New approval expands market access and revenue potential for a key vaccine.
FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.
Major product approval with first-in-class status drives future earnings.
Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.
Strategic expansion into emerging market plasma supply adds growth optionality.
AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.
AI adoption may enhance R&D productivity and pipeline value.

13 Jul – 11 Aug 2026

▲4

Takeda's new drug approvals and emerging-market push drive growth outlook

Dengue vaccine approved in India Takeda's Qdenga became the first dengue vaccine approved in India, with launch planned for early 2027. This opens a huge new market and supports Takeda's goal of 100 million doses annual capacity by 2030, boosting long-term sales potential.
New approval expands market access and revenue potential for a key vaccine.
FDA approves first-in-class narcolepsy drug The FDA approved Ozeiflur (ORZEYFUL), the first drug targeting all narcolepsy symptoms by acting on the orexin system. With about 120,000 US patients, this novel treatment could become a significant new revenue stream and showcases Takeda's R&D strength.
Major product approval with first-in-class status drives future earnings.
Indonesia plasma network investment Takeda will invest up to $30 million over two years to build Indonesia's first national plasma donation network, securing a fractionation license. This expands its plasma-derived therapies business in Southeast Asia and could lead to a new manufacturing facility, adding long-term growth.
Strategic expansion into emerging market plasma supply adds growth optionality.
AI drug discovery partnership with Nvidia Takeda is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, joining other Japanese pharma firms. This could speed up development of new treatments and improve R&D efficiency, supporting the pipeline and future product launches.
AI adoption may enhance R&D productivity and pipeline value.

Q2 202618 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.

June 202618 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.

18 Jun – 6 Jul 2026

▲4

Takeda's new CEO, AI deals, and psoriasis win drive optimism

New CEO and board refresh Julie Kim became CEO on June 24, completing an 18-month transition. The board added three external directors, bringing outside voices to 8 of 11 seats. Management highlighted three major product launches and five late-stage assets ahead, signaling a clear growth plan that supports investor confidence.
Leadership change and strategic direction are major forces behind the stock's outlook.
Psoriasis drug beats rival in Phase 3 Takeda's oral zasocitinib helped over 35% of patients achieve completely clear skin at week 16, more than double the rate of deucravacitinib. The company plans to file for approval this fiscal year. A potential new blockbuster boosts future revenue prospects.
Strong clinical data directly increases the probability of a high-value new product.
Two major AI drug discovery partnerships Takeda teamed with Boltz in June and Insilico Medicine in July, gaining advanced AI platforms to speed up drug design. The Insilico deal could be worth up to $600 million. These collaborations aim to make research more efficient and expand the pipeline.
AI partnerships can lower R&D costs and improve success rates, a key long-term value driver.
FDA accepts pediatric ENTYVIO application The FDA accepted Takeda's application to expand ENTYVIO for children aged 2 and older with ulcerative colitis and Crohn's disease, with a decision expected in early 2027. This could extend the drug's market and add sales.
Regulatory progress on an existing drug provides a near-term revenue opportunity.